Kansenshogaku Zasshi
Online ISSN : 1884-569X
Print ISSN : 0387-5911
ISSN-L : 0387-5911
Comparative Clinical Study of T-2588 and Bacampicillin for Bacterial Pneumonia by a Double-Blind Method
Hiroyuki KOBAYASHI, Shin KAWAI, Akira SAITO, Osamu YAJIMA, Masumi TOMIZAWA, Ichiro NAKAYAMA, Kiyofumi ISHIKAWA, Masao TAMURA, Takashi ITO, Kenichi TAKEUCHI, Yoshikatsu NEMOTO, Issei TANIFUJI, Masami YOSHIDA, Shigeki MORI, Kumi OKABE, Kazutoshi GOMI, Tamotsu TAKISHIMA, Shiroh IDA, Isao OHNO, Kiyoshi KONNO, Kotaro OIZUMI, Akira WATANABE, Seiichi AONUMA, Tsugushi ITO, Izumi HAYASHI, Masataka KATSU, Mieko KAWAI, Takashi INAMATSU, Kyoko URAYAMA, Shinichi OKA, Makiko FUKAYAMA, Junzaburou KABE, Hiroyoshi ISHIBASHI, Kouichirou KUDOU, Fuyuhiko HIGASHI, Yuzo FUNATSU, Hideo IKEMOTO, Kazuyoshi WATANABE, Hiroichi TANIMOTO, Yoshitaka NAKAMORI, Kunihiko YOSHIMURA, Tatsuo NAKATANI, Naohiko CHONABAYASHI, Koichiro NAKATA, Kyoichi TOZUKA, Kihachiro SHIMIZU, Atsushi SAITO, Tadashi MIYAHARA, Keimei MASHIMO, Yoshiji YAMANE, Tatsuo KATO, Kaoru SHIMADA, Shinsaku SAKURAI, Takuo TOYOSHIMA, Kentaro WATANABE, Masaru KOYAMA, Fukuo IIJIMA, Fumio MATSUMOTO, Ippei FUJIMORI, Yoshio KOBAYASHI, Masanori ADACHI, Kazufuto FUKAYA, Takeshi MITSUI, Takao OKUBO, Akira ITO, Shigeki ODAGIRI, Masanori MATSUMURA, Kaneo SUZUKI, Kou MUROHASHI, Hisako SUZUKI, Yasuhiro YOSHIIKE, Mitsuyo KIUCHI, Tsutomu FUKUDA, Masaaki ARAKAWA, Koichi WADA, Osamu SEKINE, Nobuki AOKI, Hajime TAKEDA, Masanaga TAKATOU, Eishi HIGUCHI, Fusanosuke YAMASAKU, Yasutoshi SUZUKI, Kaoru OYAMA, Nobuo OHYA, Mitsuru HAYASE, Shunsuke KITAGAWA, Kaoru SHIMOKATA, Shuzo SAKAI, Tatsuo SATAKE, Kenzoh TAKAGI, Kenichi YAMAKI, Toshihiko TAKEUCHI, Masahito KATO, Joichi KATO, Kunio NANJO, Riichiro MIKAMI, Masayoshi SAWAKI, Keiichi MIKASA, Fumiyuki KUZE, Mitsuru KAWAI, Ryoichi AMITANI, Kokichi YAMAMOTO, Hideki NISHIYAMA, Miki OKAZAKI, Fumio MIKI, Yoshiyasu IKUNO, Eiji INOUE, Minoru YOSHIYAMA, Akihito MURATA, Shinichi TANIZAWA, Kazuo SAKAMOTO, Hirozumi SAKAI, Rinzo SOEJIMA, Hiroshi KAWANE, Yoshihito NIKI, Michifumi ADACHI, Osamu KURIMURA, Tadashi MASUDA, Hideo SASAKI, Hirofumi FUKUHARA, Kouji MOCHIZUKI, Keiko KAWAMURA, Yoshiro SAWAE, Masahide TAKII, Hitoshi NAGANO, Shinichi MATSUO, Atsushi SHINODA, Tsuneo ISHIBASHI, Masahiro TAKAMOTO, Yasuko HARADA, Yoshiya KITAHARA, Masahiro NAKAMURA, Hozumi YAMADA, Osamu KATO, Kohei HARA, Yoshiteru SHIGENO, Hideaki SHIGENO, Yasumasa DOTSU, Masamoto NAKANO, Naomi ITO, Keizo MATSUMOTO, Naoto RIKITOMI, Shukuro ARAKI, Masayuki ANDO, Mineharu SUGIMOTO, Moritaka SUGA, Yasutsugu FUKUDA, Katsumasa TOKUNAGA, Etsuo KINUWAKI, Yasuhiro ETO, Hisato YAMAZAKI, Masaru NASU, Jun GOTO, Yoichiro GOTO, Takayoshi TASHIRO, Kenjiro INOUE, Hirokazu NISHITANI, Kazumine KOBARI, Yuei IRABU, Tsuneo TANAKA, Yasuyuki HAYASHI, Toyoko OGURI
Author information
Keywords: T-2588, Cefaclor, Chronic respiratory tract infection, Comparative study
JOURNAL FREE ACCESS

1986 Volume 60 Issue 9 Pages 1078-1106

Details
Download PDF (3002K)
Download citation RIS

(compatible with EndNote, Reference Manager, ProCite, RefWorks)

BIB TEX

(compatible with BibDesk, LaTeX)

Text
How to download citation
Contact us
Abstract

The clinical efficacy and safety of T-2588 were compared with those of bacampicillin hydrochloride (BAPC) in patients with bacterial pneumonia by double blind study. Patients with apparent clinical signs and symptoms were administered T-2588 (at a daily dose of 600 mg) or BAPC (at a daily dose of 1000 mg) orally for 14 days in principle. Then the clinical and bacteriological efficacy, improvement in signs and symptoms, side effect, changes of laboratory findings and clinical usefulness were assessed.
1) On the basis of committee judgement, the clinical efficacy rate was 90.7% for T-2588 and 91.8% for BAPC, respectively. No significant difference was observed between both groups . In the evaluation of clinical efficacy by each bedside physician, there was no significant difference between both groups too.
2) As for the bacteriological eradicated rate of causative organisms, there was no significant difference between two groups.
3) As for the rate of improvement in the clinical, symptoms, findings and laboratory findings, there was no significant difference between them.
4) The incidence of side effects was observed 5.2% in T-2588 group and 6.8% in BAPC alone, and there was no significant difference, in the change in laboratory findings.
5) In the evaluations usefulness judged by the committee members and the bedside physicians, there was no significant difference between both drugs.
6) From aboves, T-2588 as well as BAPC are considered to be highly useful antibacterial agents for the treatment of bacterial pneumonia.

Content from these authors
© The Japansese Association for Infectious Diseases
Previous article
Favorites & Alerts

Recently viewed articles
Predecessor

Journal of the Japanese Association for Infectious Diseases

Share this page
feedback
 Top